Cargando…
Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus
Lower extremity arterial disease (LEAD) is a major vascular complication of diabetes. Vascular endothelial cells dysfunction can exacerbate local ischemia, leading to a significant increase in amputation, disability, and even mortality in patients with diabetes combined with LEAD. Therefore, it is o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429832/ https://www.ncbi.nlm.nih.gov/pubmed/36060247 http://dx.doi.org/10.3389/fmolb.2022.929718 |
_version_ | 1784779576480628736 |
---|---|
author | Pan, Yang Luo, Yuting Hong, Jing He, Huacheng Dai, Lu Zhu, Hong Wu, Jiang |
author_facet | Pan, Yang Luo, Yuting Hong, Jing He, Huacheng Dai, Lu Zhu, Hong Wu, Jiang |
author_sort | Pan, Yang |
collection | PubMed |
description | Lower extremity arterial disease (LEAD) is a major vascular complication of diabetes. Vascular endothelial cells dysfunction can exacerbate local ischemia, leading to a significant increase in amputation, disability, and even mortality in patients with diabetes combined with LEAD. Therefore, it is of great clinical importance to explore proper and effective treatments. Conventional treatments of diabetic LEAD include lifestyle management, medication, open surgery, endovascular treatment, and amputation. As interdisciplinary research emerges, regenerative medicine strategies have provided new insights to treat chronic limb threatening ischemia (CLTI). Therapeutic angiogenesis strategies, such as delivering growth factors, stem cells, drugs to ischemic tissues, have also been proposed to treat LEAD by fundamentally stimulating multidimensional vascular regeneration. Recent years have seen the rapid growth of tissue engineering technology; tissue-engineered biomaterials have been used to study the treatment of LEAD, such as encapsulation of growth factors and drugs in hydrogel to facilitate the restoration of blood perfusion in ischemic tissues of animals. The primary purpose of this review is to introduce treatments and novel biomaterials development in LEAD. Firstly, the pathogenesis of LEAD is briefly described. Secondly, conventional therapies and therapeutic angiogenesis strategies of LEAD are discussed. Finally, recent research advances and future perspectives on biomaterials in LEAD are proposed. |
format | Online Article Text |
id | pubmed-9429832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94298322022-09-01 Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus Pan, Yang Luo, Yuting Hong, Jing He, Huacheng Dai, Lu Zhu, Hong Wu, Jiang Front Mol Biosci Molecular Biosciences Lower extremity arterial disease (LEAD) is a major vascular complication of diabetes. Vascular endothelial cells dysfunction can exacerbate local ischemia, leading to a significant increase in amputation, disability, and even mortality in patients with diabetes combined with LEAD. Therefore, it is of great clinical importance to explore proper and effective treatments. Conventional treatments of diabetic LEAD include lifestyle management, medication, open surgery, endovascular treatment, and amputation. As interdisciplinary research emerges, regenerative medicine strategies have provided new insights to treat chronic limb threatening ischemia (CLTI). Therapeutic angiogenesis strategies, such as delivering growth factors, stem cells, drugs to ischemic tissues, have also been proposed to treat LEAD by fundamentally stimulating multidimensional vascular regeneration. Recent years have seen the rapid growth of tissue engineering technology; tissue-engineered biomaterials have been used to study the treatment of LEAD, such as encapsulation of growth factors and drugs in hydrogel to facilitate the restoration of blood perfusion in ischemic tissues of animals. The primary purpose of this review is to introduce treatments and novel biomaterials development in LEAD. Firstly, the pathogenesis of LEAD is briefly described. Secondly, conventional therapies and therapeutic angiogenesis strategies of LEAD are discussed. Finally, recent research advances and future perspectives on biomaterials in LEAD are proposed. Frontiers Media S.A. 2022-08-17 /pmc/articles/PMC9429832/ /pubmed/36060247 http://dx.doi.org/10.3389/fmolb.2022.929718 Text en Copyright © 2022 Pan, Luo, Hong, He, Dai, Zhu and Wu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Pan, Yang Luo, Yuting Hong, Jing He, Huacheng Dai, Lu Zhu, Hong Wu, Jiang Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus |
title | Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus |
title_full | Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus |
title_fullStr | Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus |
title_full_unstemmed | Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus |
title_short | Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus |
title_sort | advances for the treatment of lower extremity arterial disease associated with diabetes mellitus |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429832/ https://www.ncbi.nlm.nih.gov/pubmed/36060247 http://dx.doi.org/10.3389/fmolb.2022.929718 |
work_keys_str_mv | AT panyang advancesforthetreatmentoflowerextremityarterialdiseaseassociatedwithdiabetesmellitus AT luoyuting advancesforthetreatmentoflowerextremityarterialdiseaseassociatedwithdiabetesmellitus AT hongjing advancesforthetreatmentoflowerextremityarterialdiseaseassociatedwithdiabetesmellitus AT hehuacheng advancesforthetreatmentoflowerextremityarterialdiseaseassociatedwithdiabetesmellitus AT dailu advancesforthetreatmentoflowerextremityarterialdiseaseassociatedwithdiabetesmellitus AT zhuhong advancesforthetreatmentoflowerextremityarterialdiseaseassociatedwithdiabetesmellitus AT wujiang advancesforthetreatmentoflowerextremityarterialdiseaseassociatedwithdiabetesmellitus |